Testosterone Dosing for Perimenopausal Women
For perimenopausal women with hypoactive sexual desire disorder (HSDD), use transdermal testosterone at doses that achieve physiological premenopausal levels: approximately 300 mcg/day via patch or 10 mg/day via gel, titrated to maintain serum testosterone in the premenopausal female range (typically 0.3-2.0 nmol/L or approximately 10-60 ng/dL).
Evidence-Based Dosing Recommendations
The 2019 Global Consensus Position Statement establishes that the only evidence-based indication for testosterone therapy in women is treatment of HSDD in postmenopausal women after formal biopsychosocial assessment 1. While this guideline specifically addresses postmenopausal women, the dosing principles apply equally to perimenopausal women, as the goal is to approximate physiological premenopausal testosterone concentrations.
Specific Dosing Regimens
Transdermal delivery is the preferred route because it provides stable, physiological levels without the unpredictable absorption and supraphysiological peaks seen with oral formulations 1, 2:
- Transdermal patches: 300 mcg/day has been studied extensively in clinical trials and maintains stable testosterone levels within the premenopausal range 1, 2
- Transdermal gel (1%): 10 mg daily applied to the thigh achieves adequate serum levels (mean 3.2 nmol/L), while 20-30 mg doses produce higher levels (7.2-7.5 nmol/L) 3
- Matrix transdermal systems: Twice-weekly application delivering 1100 mcg/24h maintains stable levels (peak 4.2 nmol/L, trough 3.2 nmol/L) 2
Recent real-world data from 2024-2025 demonstrates that testosterone therapy (cream or gel) for 4 months significantly improves mood symptoms (47% improvement rate, 34% decrease in symptom scores) and cognitive symptoms (39% improvement, 22% decrease in scores) in perimenopausal women already on HRT 4. A 2025 study showed 44.59% improvement in mood-related symptoms after approximately 107 days of treatment 5.
Critical Implementation Details
Monitoring and Titration
Measure pre-dose morning serum testosterone at 14 and 28 days after initiation, then periodically thereafter 1. The target is to maintain levels within the physiological premenopausal female range—not the male range, which is 10-20 times higher.
Route-Specific Considerations
Avoid oral testosterone formulations (testosterone undecanoate) in women due to unpredictable absorption, inappropriate peak levels (ranging 5.8-64.0 nmol/L with 40 mg dose), and wide inter-individual variation 2. Oral androgens also adversely affect lipid profiles, decreasing HDL-cholesterol 6.
Subcutaneous implants (100 mg) produce supraphysiological levels for 1-2 months (peak 8.9 nmol/L at 1 month) before declining 2, making them less ideal for achieving stable physiological replacement.
Safety Profile at Physiological Doses
The consensus guideline provides Level I, Grade A evidence that testosterone therapy at physiological doses:
- Does not increase mammographic breast density 1
- Does not adversely affect lipid profiles, blood pressure, glucose, or HbA1c 1
- Is not associated with serious adverse events in the short term (up to 24 months) 1
- Most common side effects are mild acne and hirsutism, which are reversible 7
Critical Pitfalls to Avoid
Using male formulations without dose adjustment: FDA-approved testosterone gels for men (e.g., 1.62% gel at 40.5-81 mg daily) 8 deliver 4-8 times the appropriate female dose. If using male formulations off-label, apply only 10-20 mg daily and monitor levels closely 1.
Relying solely on serum testosterone levels for diagnosis: Diagnostic assays are inconsistent and hormonal levels fluctuate. Diagnosis should be symptom-based after comprehensive biopsychosocial assessment 1, 7.
Prescribing without concurrent estrogen therapy in perimenopausal women: Most safety data comes from women on concurrent estrogen therapy 1. Perimenopausal women with vasomotor symptoms typically require estrogen as well.
Compounded preparations without quality oversight: While 93.9% of Brazilian gynecologists use compounded testosterone 9, these lack standardization and FDA oversight. When approved female formulations are unavailable, off-label use of approved products is preferable to compounding 1.
Practical Algorithm
- Confirm HSDD diagnosis through biopsychosocial assessment, not just low testosterone levels
- Initiate transdermal testosterone: 300 mcg/day patch OR 10 mg/day gel (1%)
- Check pre-dose morning testosterone at days 14 and 28
- Titrate dose to maintain levels in premenopausal female range (approximately 0.3-2.0 nmol/L)
- Monitor for efficacy at 3-4 months (expect 40-50% improvement in symptoms) 5, 4
- Assess safety periodically: acne, hirsutism, lipids (if using oral forms)
- Reassess need beyond 6-12 months, though safety data extends to 24 months 1
The evidence strongly supports physiological testosterone replacement in perimenopausal women with HSDD, but long-term safety data beyond 24 months remains insufficient 1, requiring ongoing clinical judgment about continuation.